Journal of Nuclear Medicine: 63 (5)

May 1, 2022; Volume 63,Issue 5

Cover image

FEATURED ARTICLE

CD8-Targeted PET Imaging of Tumor-Infi ltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. Michael Farwell et al. See page 720.

In this issue

Issue highlights

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
First-in-Human Assessment of ¹¹C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
Tau PET imaging with ¹⁸F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
Radiation Dosimetry in ¹⁷⁷Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to